Deal Doctor: A Diagnostic Template for At-Risk Opportunities in the Pipeline

The Tuesday morning that broke the forecast

Picture a mid-market software company with roughly $50M in ARR and eleven quota-carrying reps. It is the second Tuesday of the last month of the quarter. The forecast call opens and the number on the board looks fine — commit plus best case comfortably clears the target. Three weeks later, the quarter closes 14% short. Nothing dramatic happened. No competitor swooped in with a knife-fight discount. No champion resigned. What happened is what almost always happens: six deals that everybody *felt* good about stopped moving, and nobody had a shared language for saying so out loud.

Go back and look at those six deals on that Tuesday and the warning signs are all sitting in the CRM in plain view. One had a last-activity date 38 days old but was still sitting in Negotiation because the rep had logged a "verbal yes" in week two and never moved it. One had a stage duration three times the historical average for that stage. Two had no contact record anywhere in the account above the director level, on a purchase that would need a CFO signature. One had a mutual action plan that hadn't been touched since the demo. And one, the biggest, had a champion who had gone from replying in four hours to replying in six days — a decay curve nobody was measuring.

The problem is not that reps are careless. The problem is that pipeline inspection, as it is normally practiced, is a conversation about *feelings* dressed up as a conversation about data. A manager asks "how's Acme looking?" and a rep says "good, they're excited, we're just waiting on legal." Both statements can be true and the deal can still be dead. The rep isn't lying. The rep genuinely doesn't know, because nobody handed them an instrument that distinguishes "waiting on legal" from "the person who told me we're waiting on legal has no authority to start legal."

That is the gap the Deal Doctor fills. It is not a methodology in the grand sense — it is deliberately smaller than that. It is a one-page form with six fields that any rep can fill out in eight minutes for any opportunity, and that any manager can read in ninety seconds and immediately know three things: how sick is this deal, what specifically is wrong with it, and what are we doing about it by Friday. The metaphor matters more than it sounds. A doctor doesn't ask a patient "how do you feel about your heart?" A doctor takes a pulse, runs a scan, names a condition, and writes a prescription. The steps are boring and identical every time, and that is exactly why they work at scale.

The adjacent value shows up faster than the deal-level value. Once three or four reps have filled out the same Diagnostic on their worst deals, the aggregate view starts to talk. If seven of the twelve at-risk opportunities in a quarter share the root cause "no verified economic buyer before proposal," you no longer have twelve deal problems. You have one process problem, sitting upstream in your qualification criteria, and you can fix it with a stage-exit rule instead of twelve rescue conversations. That's the real return: the template is a deal tool that quietly doubles as a diagnostic instrument for the sales process itself.

How the three-layer diagnostic actually works

Layer one is vital signs — everything the CRM already knows without a human interpreting it. Pull four numbers and nothing else. Days since last meaningful activity (a logged call, meeting, or inbound reply from the prospect; an outbound email you sent that nobody answered is not activity, and letting reps count it is the single most common way this layer gets gamed). Days in current stage, compared against your own median for that stage. Total age versus your median cycle length for that deal size band. And close-date slip count — how many times the date has been pushed. That last one is the most underrated signal in pipeline management, because a deal that has slipped three times has told you three times that the rep's model of the buying process is wrong, and the fourth date is being generated by the same broken model.

Layer two is the org scan, and this is where a qualification framework earns its keep. MEDDPICC — Metrics, Economic Buyer, Decision Criteria, Decision Process, Paper Process, Identify Pain, Champion, Competition — is the common choice because its eight dimensions map cleanly onto the eight ways a deal dies. Score each 1–5, but score them against evidence, not confidence. The rule that makes scoring honest: you may not score above a 3 on any dimension without naming the artifact that proves it. Economic Buyer is a 5 when you have met them and they have stated the business outcome in their own words; it is a 2 when your champion has told you their name. Paper Process is a 4 when you have seen the actual procurement steps and know who signs; it is a 1 when someone said "we'll handle that at the end." Force the artifact and the average score in most pipelines drops a full point overnight, which is not a morale problem — it's the first accurate picture anyone has had.

Layer three is the prescription, and it is deliberately constrained to three options. *Re-engage* means the deal is fundamentally qualified and simply stalled — the pain is real, the champion is real, the money exists, and momentum lapsed. *Rescue* means there is a specific structural defect that must be repaired before the deal can advance: no access to the economic buyer, an undefined decision process, a competitor who has written the requirements. *Qualify out* means the deal is not going to close in any timeframe you're forecasting, and continuing to carry it is costing you real selling hours and corrupting the forecast for everyone downstream.

The connective tissue between layer two and layer three is the root cause field, and it is the hardest part of the whole template to enforce. It must be one sentence, it must be falsifiable, and it must name a specific missing thing. "The deal is stalled" is not a root cause. "Champion is a director who has never sponsored a purchase over $100K and cannot get us in front of the VP of Finance" is a root cause, because you can immediately see what action would falsify it. Managers should reject any Deal Doctor whose root cause could be pasted onto a different deal without editing. If it's portable, it's not a diagnosis.

The final field is the action plan: exactly three steps, each with a named owner and a calendar date, and at least one of them must involve a person in the customer's organization you have not yet spoken to. That last constraint sounds arbitrary. It isn't. Deals stall because the coverage map is too narrow, and the default rescue instinct — email the same champion again, with more urgency — reinforces exactly the condition that caused the stall.

Numbers, ranges, and what a healthy instrument looks like

Resist the temptation to import benchmark thresholds from a vendor report. The thresholds that matter are the ones from your own closed-won history, and pulling them is a two-hour exercise in a CRM report builder. Take the last twelve months of closed-won opportunities, segment by deal size band, and calculate the median days-in-stage for each stage. Then do the same for closed-lost. In most pipelines the two distributions separate cleanly by mid-funnel: won deals move through evaluation and negotiation at a fairly tight median, while lost deals fan out into a long tail. Where those distributions diverge is your at-risk threshold, and it will typically land somewhere between 1.5× and 2× the won-deal median for that stage. Use that, not a round number you read somewhere.

Do the same for silence. Compute the distribution of maximum activity gaps inside your closed-won deals. The useful statistic is the 90th percentile — the longest quiet stretch that a deal you eventually won actually survived. If 90% of your won deals never went more than about two weeks without prospect-initiated contact, then a three-week gap is genuinely anomalous in your business and deserves a diagnostic, even if it would be unremarkable in a business with twelve-month enterprise cycles. Two SaaS companies of identical size can have thresholds that differ by a factor of three, which is precisely why borrowed benchmarks produce false alarms and missed emergencies at the same time.

For scoring, a few operating ranges hold up well across teams. A deal with any MEDDPICC dimension at 1 should not be forecast in commit, full stop — a single zeroed dimension is usually load-bearing. A deal with an average above 4 that is still stalling almost always has a vital-signs problem rather than a coverage problem, which means the diagnosis is about timing, competing priorities, or a budget cycle, not about qualification. And the composite is less informative than the minimum: two deals both averaging 3.4 behave completely differently if one has all threes and the other has sixes worth of fives paired with a 1 on Decision Process.

On volume: a single rep with a healthy pipeline should be running the full Diagnostic on three to five opportunities a week, not on their entire book. If your at-risk filter is surfacing twenty deals per rep, the filter is miscalibrated or — more likely — the pipeline is padded and the real problem is upstream entry criteria. Time-box the exercise at eight to ten minutes per deal. Longer than that and reps start writing narratives instead of diagnoses, and the template dies of its own weight within a month.

The metric to watch at the team level is qualify-out rate, and it should be uncomfortable. A functioning weekly triage should be retiring meaningful volume from the pipeline every month — deals that were never going to close and were occupying calendar time. When a rep qualifies out a $200K opportunity they'd been carrying for five months, they are handing back the four to six hours a month that deal was consuming in follow-up, internal updates, and forecast defense. Across a team of ten that recovered time is a substantial fraction of a headcount, redirected from deals that cannot close to deals that can. Managers who treat qualify-outs as failures will get zero of them and their forecast will stay fictional; managers who publicly congratulate the first few will get honest pipelines within a quarter.

One more measurement worth instrumenting: diagnosis-to-outcome accuracy. Every time you write a prescription, you are making a prediction. Log it. Ninety days later, check what actually happened to the deals you marked re-engage, rescue, and qualify out. If your qualify-outs are quietly closing six months later, your bar is too aggressive. If your rescues are dying at the same rate as deals you never touched, your rescue plays aren't working and the template is generating paperwork instead of outcomes. Most teams never close this loop, which is why most deal-review rituals never get better than they were on day one.

Trade-offs, alternatives, and where this template is the wrong tool

The Deal Doctor competes with several adjacent approaches, and picking the wrong one wastes a quarter.

Automated health scoring — the red/yellow/green badge that a revenue intelligence platform or a CRM formula field computes from activity data, email sentiment, and stage progression — is faster and covers 100% of the pipeline with zero rep effort. Its weakness is that it produces a symptom, not a diagnosis. Knowing a deal is yellow tells you nothing about whether the fix is a champion coaching session or a procurement introduction. The genuinely good pattern is to use automated scoring as the *trigger* and the manual Diagnostic as the *response*: let the machine flag which twenty deals deserve attention, and let a human do the eight-minute scan on the five that matter. Using scoring alone gives you an anxiety dashboard; using the template alone means you're picking which deals to inspect by gut.

Full methodology rollout — Command of the Sale, MEDDPICC as an org-wide operating system, a formal value-selling program — is strictly more powerful and strictly more expensive. It requires training budget, manager enablement, CRM field work, and roughly two quarters before behavior actually changes. The Deal Doctor is a borrowed subset: it uses MEDDPICC's vocabulary without demanding the full implementation. If you already run a methodology, the template becomes its inspection ritual and the two reinforce each other. If you don't, the template gives you maybe 60% of the diagnostic benefit for about 5% of the change-management cost, and it doubles as a low-risk pilot — if reps find the scan useful on their own deals, you have your business case for the larger program.

Manager-led deal reviews, where a senior leader interrogates a rep in front of peers, produce excellent diagnoses and terrible scale. They're bounded by the manager's calendar and they generate defensiveness, which suppresses exactly the honest information you need. The template inverts the flow: the rep does the diagnosis privately, and the review becomes a conversation about the prescription. That single change — arriving with a filled-out form instead of arriving to be examined — is worth more than any coaching technique layered on top of the old format.

There are also situations where the Deal Doctor is simply the wrong instrument. In genuine transactional motions — sub-$10K, single decision maker, cycles measured in days — the diagnostic overhead exceeds the deal value, and the right tool is a volume-based cadence rule. In very large enterprise pursuits with twenty stakeholders and eighteen-month cycles, a six-field form is too coarse; those need a full account plan with a stakeholder power map, and the template at best becomes a monthly summary layer on top. And in a brand-new market where nobody has a defined buying process yet, "no decision process" will score a 1 on every deal you have, which makes the score uninformative — there, the useful diagnostic is about whether the buyer can *create* a process, not whether one exists.

The trade-off worth naming honestly: this template optimizes for consistency over nuance. It will occasionally mark a genuinely winnable deal as qualify-out because the coverage looks thin on paper while the rep has real, unrecorded signal. That's the cost of an instrument any eleven people can use the same way. The mitigation is a rep override with a written reason, reviewed monthly — if a rep's overrides are consistently right, you've learned something about your scoring rubric; if they're consistently wrong, you've learned something about that rep's forecast.

The failure modes that kill this in month two

Scoring theater. Within three weeks of rollout, MEDDPICC scores start creeping upward and everything averages 4.2. Nobody decided to do this; it's just what happens when a number is visible to your manager and nothing forces it to be true. The fix is the evidence rule stated earlier — no score above 3 without a named artifact — plus a periodic spot-audit where a manager picks one deal at random and asks the rep to produce the proof behind their Economic Buyer score. Two audits are usually enough to recalibrate a whole team, and they work better than any amount of exhortation about honesty.

The portable root cause. Reps write "needs more urgency" or "waiting on their timeline" and technically the field is filled. These pass a compliance check and fail completely at their actual job. The enforcement heuristic is simple and mechanical: read the root cause with the company name removed. If you can't tell which deal it belongs to, send it back.

Rescue-everything syndrome. The prescription field has three options and one of them feels like giving up, so reps pick rescue for deals that are plainly dead. The resulting action plan is three tasks nobody intends to complete, and the deal sits in the pipeline another two months with a diagnostic attached, which is worse than no diagnostic at all because now it looks managed. Two counters work. First, cap rescues — if a rep runs the template on five opportunities and prescribes rescue for all five, the manager rejects the batch and asks which one is really dead. Second, make qualify-out socially rewarded: name it in the team meeting, and be specific about the hours it freed.

Diagnose and abandon. The template gets filled out, the action plan gets written, and then nobody checks whether the three steps happened. The exercise degrades into weekly homework with no consequence and reps correctly conclude it's theater. The structural fix is a mandatory 14-day re-diagnosis on every deal prescribed re-engage or rescue: same form, same fields, side by side with the original. If vital signs haven't improved and the coverage scores haven't moved, the prescription failed and the next prescription is qualify-out. A diagnostic without a follow-up appointment is a note in a drawer.

Instrumenting the wrong layer. Teams that fall in love with the vital-signs layer — because it's automatable and produces charts — end up chasing activity metrics and generating reflexive check-in emails that manufacture a last-activity date without changing anything real. The vital signs tell you *that* something is wrong. Only the org scan tells you *what*. If your weekly triage is producing more emails and no new stakeholder meetings, you have automated the symptom and skipped the diagnosis.

Death by field creep. Someone adds a field. Then someone adds a picklist. Within a quarter the eight-minute Diagnostic takes twenty-five minutes and adoption quietly collapses. Defend the six fields aggressively. Anything genuinely worth capturing beyond them belongs in the account plan, not here. The template's power is entirely a function of its being small enough that a rep will actually complete it on a Monday morning when they'd rather be selling.

What happens after the diagnosis — the adjacent workflows

The output of a Deal Doctor is only as good as the play that follows it, and there are really only a handful of plays worth building.

For re-engage, the mistake is treating it as a follow-up problem. The deal went quiet because your priority stopped being the buyer's priority, and another email won't change that. The play is to return with something new — a peer data point, a change in their market, a revised model reflecting something that shifted on their side. The re-engagement that works asks for a decision about whether to continue, not for a status update: giving the buyer explicit permission to say "not this year" gets you a real answer, and a clean no in March is worth more than a maybe you carry until December.

For rescue, the play depends entirely on which dimension scored low. Missing economic buyer? The move is to prepare your champion to make the introduction rather than to demand it — walk them through the three questions a finance leader will ask about payback, cash impact, and how this ranks against competing requests, then offer to join the meeting. A champion who can't answer those questions will keep quietly declining to arrange it, and no amount of pressure fixes that. Undefined decision process? Build the mutual action plan backwards from the buyer's target date, and let the gaps in the timeline do the arguing. Competitor wrote the requirements? Reframe the criteria themselves rather than answering their questions better than they do.

For qualify-out, do not simply close-lost and move on. Capture the reason code, and — this is the part everybody skips — capture the stage at which the fatal gap *first became visible*. That single field, aggregated across a quarter, tells you exactly where your qualification is leaking. If most fatal gaps were visible at discovery but weren't acted on until negotiation, you don't have a rescue problem; you have a stage-exit-criteria problem, and the highest-leverage fix is upstream of every deal you're currently trying to save.

There's a natural extension worth mentioning because it costs almost nothing: the same three-layer structure works on renewals and expansion. Swap the vital signs for product usage trend, support ticket sentiment, and days since the last executive touch. Swap the org scan for stakeholder coverage against the original buying committee — the classic renewal failure is that your champion left eight months ago and nobody noticed. The prescription options become re-engage, rescue, or flag-for-churn. Teams that run one diagnostic vocabulary across new business and post-sale get a genuinely unified view of revenue risk, and the shared language means an account manager and an AE can hand a deal back and forth without translating.

The last adjacency is forecasting. Once diagnoses are being logged consistently, the root-cause field becomes a leading indicator that no stage-based forecast can produce. Stage tells you where a deal is; root cause tells you why it might not arrive. A commit category filtered to exclude every opportunity with an open unresolved root cause is a materially different — and more accurate — number than the one your reps submit. That's the quiet endgame here: a template that starts as a rescue tool for sick deals ends up as the most honest input in your revenue model.

Related questions

How is this different from a standard pipeline review?

A pipeline review inspects everything shallowly and is driven by the manager's questions. This Diagnostic goes deep on three to five at-risk opportunities, is completed by the rep before the meeting, and ends in a written prescription with dates. The review becomes a conversation about the plan, not an interrogation.

Do I need MEDDPICC specifically?

No. Any structured qualification framework works — BANT, SPICED, or a custom set of dimensions. What matters is that the dimensions are fixed, scored on a consistent scale, and backed by evidence rather than confidence. MEDDPICC is popular mainly because its eight dimensions map cleanly onto the eight ways complex deals die.

Who should fill out the template — the rep or the manager?

The rep, always. The diagnosis is worthless if it's extracted under pressure, and the rep holds the raw information. The manager's job is to audit the evidence behind scores, reject portable root causes, and hold the 14-day re-diagnosis. Manager-authored diagnostics produce compliance, not insight.

Can this run inside the CRM instead of a document?

Yes, and it should eventually. Six custom fields on the opportunity object plus a saved view is enough. The advantage is aggregation — once root causes and prescriptions are structured data, you can see which failure patterns repeat across the team and fix the process upstream instead of rescuing deals one at a time.

What if the diagnosis says qualify out but the deal is in my commit?

Then your commit was wrong, and the sooner that surfaces the better. Pull it out, tell your manager the specific gap, and offer the honest replacement number. A forecast that quietly carries dead deals costs the whole organization far more in downstream planning than one uncomfortable correction.

FAQ

How long should filling out the Deal Doctor take?

Eight to ten minutes per opportunity once a rep has done it three or four times. The first one takes twenty because pulling activity dates and honestly scoring coverage is unfamiliar. If it's still taking twenty minutes in week three, the template has too many fields or reps are writing narrative instead of diagnosis. Time-box it explicitly and enforce the limit — the discipline of brevity is what makes it survivable as a weekly habit.

What counts as "last activity" for the vital signs layer?

A meaningful two-way interaction: a meeting held, a call connected, an inbound reply from the prospect, or a document they actually opened and responded to. An outbound email that got no answer is not activity. Automated sequence touches are not activity. This distinction is the most commonly gamed part of the whole instrument, and letting it slide turns the vital-signs layer into decoration within a month.

Should the template be used on healthy deals too?

Occasionally, and it's a genuinely useful calibration exercise. Run it on a deal you're certain will close and you'll frequently discover a 2 on Paper Process that you'd never examined because everything else felt good. Once a quarter on your top three commit deals is a reasonable cadence. Running it on every deal every week is how the practice dies of overhead.

How do I get reps to qualify out honestly when their pipeline coverage ratio is a metric?

You can't, until you fix the incentive. If coverage is measured on raw pipeline dollars, every rep is rationally punished for honesty. Measure coverage on qualified pipeline — deals that pass a minimum diagnostic bar — and the incentive flips. Until that change lands, expect inflated pipelines regardless of how good your template or your intentions are.

What's the right cadence for re-diagnosis?

Fourteen days for anything prescribed re-engage or rescue. That's long enough for a real action to have landed and short enough that a failing prescription doesn't burn a month. Compare the new vital signs and coverage scores directly against the original. If nothing moved, the prescription failed, and the default next prescription is qualify-out rather than a second rescue attempt.

Does this work for a solo founder or a two-person sales team?

Yes, and arguably better, because there's no compliance overhead and no incentive to inflate. A founder running the Diagnostic on their four largest open opportunities every Monday gets most of the value: forced honesty about economic buyer access, a named root cause, and three dated actions. The aggregate pattern analysis takes longer to become meaningful with small numbers, but the per-deal discipline is immediate.

Sources

• MEDDIC Academy — MEDDPICC overview
• Winning by Design — sales frameworks and blueprints
• HubSpot — sales pipeline management
• Salesforce — what is a sales pipeline
• Harvard Business Review — sales and negotiation research
• Gong Labs — sales research and data
• Clari — revenue operations resources
• McKinsey — growth, marketing and sales insights

Related on PULSE

• [The Value-Add Upsell: Template for Identifying Cross-Sell Opportunities in Accounts](/knowledge/st0699)
• [Forgotten Follow-Ups: A Template for Re-Engaging Stalled Opportunities](/knowledge/st0674)
• [Pipeline Review to Revenue: Template for a Data-Driven Sales Sprint Session](/knowledge/st0784)
• [The Weekly Pipeline Review Template That Doubles Close Rates](/knowledge/st0655)
• [Deal Desk Simulation: Cross-Functional Approval Process Roleplay](/knowledge/st0710)
• [Top 10 deal review role-play scenarios for sales teams](/knowledge/st0570)